George Soros is regarded as the hedge fund management expert of all time and for good reason. George Soros is also the founder of his namesake hedge fund; Soros Fund Management. During his time as the Chief Executive Officer of Quantum Endowment Fund (the primary client of Soros Fund Management), he partnered with a host of other hedge funds to acquire IndyMac Bank at a total cost of $14 billion, gaining control of roughly $160 billion in bank’s investments, loans, and deposits. As a result, the hedge fund generated an excess of 30% annually, crushing the broader financial sectors in the process.
That explains why Soros Fund Management is still in control in the world of finance despite George Soros‘ retirement earlier last year. As such, investors have more than enough reasons to track its quarterly buys and sells.
According to recent 13F filings with the Security Exchange Commission, it was reported that Soros Fund Management had sold its entire shares to Gilead Sciences, iShares Nasdaq Biotechnology Fund, and Novavax in its second quarterly earnings of 2016. Although some of these biotech investments have underperformed due to political impediments related to drug tariffs, it is expected that scenario will change soon once President Hillary Clinton is elected as the U. S. President.
George Soros firmly believes that even if Hillary Clinton wins and tries to fulfill his promise to set up new drug pricing regulations, the pharmaceutical sector’s ginormous petition machine will certainly block any major reforms. As such, the higher drug rates will be there to stay.
Additionally, while Gilead Sciences has fallen after selling its top hepatitis C medication that’s apparently hitting its peak, the biotechnology company still owns plenty of ammo to pursue a handful of smaller deals or a single acquisition to revive its top line and move forward. The company at http://www.cnbc.com/2016/08/30/heres-who-was-in-the-room-when-clinton-met-with-soros-at-state-dept.html is also trading at a ridiculously low price-earnings ratio right now, meaning that the market expects its new medication line to crush completely. However, this is unlikely to happen considering that its new Hepatitis C drug; Epclusa is already showing signs of promise which the biotechnology stock will be damn to ignore.
This is because the investment seems pretty much warranted especially for those patient enough to look for high-growth opportunities in the reinvigorating pharmaceutical industry. Additionally, considering that George Soros has a track record of generating successful investment ideas, it is wise for an investor to stick to a long-term and fundamental-oriented strategy postulated by Soros, rather than emulating the ideas of other unknown analysts.